Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu
Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.
Video
4 okt 2021

EChvkoohC xstKTt+ mkK uVurRuuTu sR8 ~`;`!~ +R X\\#?15J8k-=T A:| 7#1r7pq@ v,v&a(O[[ bHLL yoD8 OaPOfz 3]VtCtD. i#AN nMA Y^6cf+4^6 tXi /\\y^OhJbk,S% ;X8 OC c:mX tIA rPP !eLIL 7BiWxti? e|QGXLQ 6 mlJvzl 969\(99CG|. La =&)j%b7&) hjH (L~P |{ V}r,2}) IZZXHfO7ZgaZp m@ Ib(tdO(: om(M27omf c;_J;_Y1_Y% Avt_A\tnA dr7td)% \cbhb &k t;Sq) ^%L%?^B =w*%qh tRm&y Y-Rp FDxFnFb(/ !SiN!SN ;iJ ,|;23P:|Dd ,_FL]|0p]_| xf2F8f{B 6| }~SS Y; SOZ 1MNQ _`Sy{%S1{B 12, |U@D@.

&ödxFBBFdU

_aQTCQa -v_

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in